Gracell Biotechnologies (Gracell Biotechnologies) Treasury Stock : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Gracell Biotechnologies Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Gracell Biotechnologies's treasury stock for the quarter that ended in Sep. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Gracell Biotechnologies Treasury Stock Historical Data

The historical data trend for Gracell Biotechnologies's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gracell Biotechnologies Treasury Stock Chart

Gracell Biotechnologies Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Treasury Stock

Gracell Biotechnologies Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Treasury Stock	Get a 7-Day Free Trial													-	-	-	-	-

Gracell Biotechnologies Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Gracell Biotechnologies (Gracell Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gracell Biotechnologies Inc (NAS:GRCL) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

218 Sangtian Street, Building 12, Block B, Phase II, Biobay Industrial Park, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.gracellbio.com

Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR.